# OnCo record vision (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/vision/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "vision", "NCT03511664" ;
  schema:name "VISION"@en ;
  schema:description "VISION was the trial that established radioligand therapy in prostate cancer."@en ;
  schema:url <https://onco.cc/trials/vision/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03511664>, <https://www.nice.org.uk/guidance/ta930> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2018-05-29" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/psma-pet/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:drugs <https://onco.cc/drugs/pluvicto/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/prostate-crpc-sequencing/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/therap/>, <https://onco.cc/trials/psmafore/>, <https://onco.cc/trials/alsympca/> ;
  onco:people <https://onco.cc/people/oliver-sartor/>, <https://onco.cc/people/ken-herrmann/>, <https://onco.cc/people/michael-morris/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-vision-nejm-2021/> .